natgillin/translations-raw huggingface dataset:
The reconstituted solution will be withdrawn from the vial and added to an infusion bag of 0.9% sodium chloride in the hospital. 
V bolnišnici se pripravljena raztopina odvzame iz viale in doda v infuzijsko vrečko z 0,9 % raztopino natrijevega klorida.
Tedizolid is bacteriostatic against enterococci, staphylococci, and streptococci in vitro. 
In vitro je tedizolid bakteriostatičen proti enterokokom, stafilokokom in streptokokom.
Serotonergic effects at doses of tedizolid phosphate up to 30-fold above the human equivalent dose did not differ from vehicle control in a mouse model that predicts brain serotonergic activity. 
Pri mišjem modelu, ki napoveduje serotoninergično delovanje v možganih, se pri odmerkih tedizolid fosfata, do 30-krat večjih od enakovrednega odmerka pri ljudeh, serotoninergični učinki niso razlikovali od kontrole z vehiklom.
• Dry mouth, constipation, indigestion, pain/discomfort in the belly (abdomen), retching, dry heaving, bright red blood in the stool 
• suha usta, zaprtost, prebavne motnje, bolečine/neprijeten občutek v trebuhu, siljenje na bruhanje, sprožanje refleksa bruhanja, svetlo rdeča kri v blatu
• Joint pain, muscle spasms, back pain, neck pain, pain/discomfort in limbs, decrease of grip strength 
• bolečine v sklepih, mišični krči, bolečine v hrbtu, bolečine v vratu, bolečine/neprijeten občutek v okončinah, zmanjšanje moči prijema
What you need to know before you take Sivextro 
Kaj morate vedeti, preden boste vzeli zdravilo Sivextro
Therefore, orally administered Sivextro can result in inhibition of BCRP at the intestinal level. 
Pri peroralni uporabi zdravila Sivextro lahko zato pride do zaviranja BCRP na črevesni ravni.
These events have been observed with another member of the oxazolidinone class when administered over a duration exceeding that recommended for tedizolid phosphate. 
Te učinke so opazili pri uporabi drugega zdravila iz skupine oksazolidinonov, ko so ga uporabljali dlje, kot je priporočeno za tedizolid fosfat.
• Fungal infections of skin , mouth and vagina (oral / vaginal thrush) 
• glivične okužbe kože, ust in nožnice (ustne/vaginalne "gobice")
Myelosuppression (including anaemia, leucopenia, pancytopenia and thrombocytopenia) has been reported in patients treated with another member of the oxazolidinone class and the risk of these effects appeared to be related to the duration of treatment. 
O mielosupresiji (vključno z anemijo, levkopenijo, pancitopenijo in trombocitopenijo) so poročali pri bolnikih, ki so se zdravili z drugim zdravilom iz skupine oksazolidinonov.
In ABSSSI, the types of infections treated were confined to cellulitis/erysipelas or major cutaneous abscesses, and wound infections only. 
Pri akutnih bakterijskih okužbah kože in mehkih tkiv so bile zdravljene vrste okužb omejene samo na celulitis/šen ali večje kožne abscese in okužbe ran.
What Sivextro looks like and contents of the pack Sivextro is a white to off-white powder for concentrate for solution for infusion in a glass vial. 
Zdravilo Sivextro je bel do skoraj bel prašek za koncentrat za raztopino za infundiranje v stekleni viali.
Oral and intravenous tedizolid phosphate is a prodrug that is rapidly converted by phosphatases to tedizolid, the microbiologically active moiety. 
Peroralni in intravenski tedizolid fosfat je predzdravilo, ki ga fosfataze hitro pretvorijo v mikrobiološko aktivni tedizolid.
Adrenergic agents 
Adrenergične učinkovine
• Itching (including itching due to allergic reaction), hair loss, acne, red and/or itchy rash or hives, 
• srbenje (vključno s srbenjem zaradi alergijske reakcije), izpadanje las, akne, rdeč in/ali srbeč izpuščaj ali koprivnica, prekomerno znojenje
Vulvovaginal pruritus 
Okvara ledvic
Therefore, orally administered tedizolid phosphate can result in inhibition of BCRP at the intestinal level. 
Pri peroralni uporabi tedizolid fosfata lahko zato pride do zaviranja BCRP na črevesni ravni.
Monoamine oxidase inhibition 
Zaviranje monoaminooksidaze
Sivextro 200 mg film-coated tablets 
Sivextro 200 mg filmsko obložene tablete
If you are given more Sivextro than you should Tell your doctor or nurse immediately if you are concerned that you may have been given too much Sivextro. 
Če ste prejeli večji odmerek zdravila Sivextro, kot bi smeli Če vas skrbi, da ste morda prejeli preveč zdravila Sivextro, se takoj posvetujte z zdravnikom ali medicinsko sestro.
No dosage adjustment is required (see section 5.2). 
Prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
It is available in 6 × 1 tablets in perforated unit-dose blisters. 
Na voljo je v perforiranih deljivih pretisnih omotih s posameznimi odmerki, ki vsebujejo 6 x 1 tableto.
A clinical study comparing the single dose (2 mg) pharmacokinetics of midazolam (CYP3A4 substrate) alone or in combination with tedizolid phosphate (once-daily 200 mg oral dose for 10 days), demonstrated no clinically meaningful difference in midazolam Cmax or AUC. 
Klinična študija, v kateri so primerjali farmakokinetiko enkratnih odmerkov (2 mg) midazolama (substrat CYP3A4) samega ali v kombinaciji s tedizolid fosfatom (200-mg peroralni odmerek enkrat dnevno 10 dni), ni pokazala klinično pomembne razlike v Cmax ali AUC midazolama.
If you forget to take your medicine, take the dose as soon as possible anytime up to 8 hours prior to the next scheduled dose. 
Če ste pozabili vzeti odmerek, ga vzemite čim prej, in sicer kadar koli do najmanj 8 ur pred naslednjim načrtovanim odmerkom.
There are limited data in patients on the interaction between serotonergic agents and tedizolid phosphate. 
Podatkov o medsebojnem delovanju serotoninergičnih zdravil in tedizolid fosfata pri bolnikih je malo.
6 × 1 tablets in aluminum/Polyethylene Terephthalate (PET)/Paper foil and polyvinyl chloride (PVC)/polyvinylidene chloride (PVdC) clear film perforated child-resistant unit-dose blisters. 
6 x 1 tableta v perforiranih za otroke varnih deljivih pretisnih omotih s posameznimi odmerki iz aluminijaste/polietilen tereftalatne (PET)/papirne folije in prosojne folije iz polivinilklorida (PVC)/polivinilidenklorida (PVdC).
The following adverse reactions have been identified in two comparative pivotal Phase 3 studies and one post-authorisation study with Sivextro (Table 1). 
V dveh primerjalnih ključnih študijah 3. faze in eni študiji po pridobitvi dovoljenja za promet z zdravilom Sivextro so ugotovili naslednje neželene učinke (preglednica 1).
Tedizolid phosphate is converted by endogenous plasma and tissue phosphatases to the microbiologically active moiety, tedizolid. 
Endogene fosfataze v plazmi in tkivih pretvorijo tedizolid fosfat v mikrobiološko aktivni tedizolid.
Contact your doctor, pharmacist or nearest hospital casualty department as soon as possible if you have taken more tablets than you should, and take your medicine with you. 
Če ste vzeli večji odmerek zdravila Sivextro, kot bi smeli Če ste vzeli več tablet, kot bi smeli, čim prej obiščite zdravnika, farmacevta ali nezgodni oddelek najbližje bolnišnice in vzemite zdravilo s seboj.
What Sivextro is and what it is used for What you need to know before you take Sivextro How to take Sivextro 
Kaj je zdravilo Sivextro in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Sivextro Kako jemati zdravilo Sivextro Možni neželeni učinki
What Sivextro contains 
Kaj vsebuje zdravilo Sivextro
At steady state, tedizolid mean (SD) Cmax values of 2.2 (0.6) and 3.0 (0.7) mcg/mL and AUC values of 25.6 (8.5) and 29.2 (6.2) mcg·h/mL were similar with oral and IV administration of tedizolid phosphate, respectively. 
2,2 (0,6) oziroma 3,0 (0,7) µg/ml in vrednosti AUC 25,6 (8,5) oziroma 29,2 (6,2) µg·h/ml.
Each film-coated tablet contains 200 mg tedizolid phosphate. 
Ena filmsko obložena tableta vsebuje 200 mg tedizolid fosfata.
Safety was additionally evaluated in a randomized, double-blind, multicenter study conducted in China, the Philippines, Taiwan, and the US, which included a total 292 adult patients treated with tedizolid phosphate 200 mg administered IV and/or oral once daily for 6 days, and 297 patients treated with linezolid 600 mg administered IV and/or oral every 12 hours for 10 days for ABSSSI. 
Študija je vključevala skupno 292 odraslih bolnikov, zdravljenih z 200 mg tedizolid fosfata intravensko in/ali peroralno enkrat dnevno 6 dni, in 297 bolnikov, zdravljenih s 600 mg linezolida intravensko in/ali peroralno vsakih 12 ur 10 dni, za zdravljenje akutnih bakterijskih okužb kože in mehkih tkiv.
If less than 8 hours remains before the next dose, then the physician should wait until the next scheduled dose. 
Če je do naslednjega odmerka manj kot 8 ur, mora zdravnik počakati do naslednjega načrtovanega odmerka.
C-labeled tedizolid phosphate under fasted conditions, the majority of elimination occurred via the liver with 81.5% of the radioactive dose recovered in faeces and 18% in urine, with most of the elimination (>85%) occurring within 96 hours. 
81,5 % radioaktivnega odmerka se je izločilo v blatu in 18 % v urinu.
Tedizolid was positive in an in vitro CHL cell chromosomal aberration assay, but negative for genotoxicity in other in vitro assays (Ames, mouse lymphoma mutagenicity) and in vivo in a mouse bone marrow micronucleus assay. 
Medtem ko je bil v preskusu in vitro s kromosomskimi aberacijami v pljučnih celicah kitajskega hrčka rezultat pozitiven, je bil negativen za genotoksičnost v drugih preskusih in vitro (Ames, mutagenost v mišjem limfomu) in v preskusu z mikrojedri v mišjem kostnem mozgu in vivo.
The pharmacokinetics of tedizolid in elderly healthy volunteers (age 65 years and older, with at least 5 subjects at least 75 years old; n=14) was comparable to younger control subjects (25 to 45 years old; n=14) following administration of a single oral dose of tedizolid phosphate 200 mg. 
Po zaužitju enkratnega 200 mg peroralnega odmerka tedizolid fosfata je bila farmakokinetika tedizolida pri starejših zdravih prostovoljcih (starih 65 let in več, med katerimi je bilo najmanj 5 preiskovancev starih vsaj 75 let, n = 14) primerljiva kot pri mlajših preiskovancih iz kontrolne skupine (od 25 do 45 let, n = 14).
Dysgeusia Tremor Paraesthesia Hypoaesthesia 
Bolezni živčevja glavobol zaspanost omotica disgevzija tremor parestezija hipestezija
How to take Sivextro 
Kako jemati zdravilo Sivextro
After reconstitution each mL contains 50 mg tedizolid phosphate. 
Po rekonstituciji en ml vsebuje 50 mg tedizolid fosfata.
• Nausea 
• bruhanje
Clostridioides difficile associated diarrhoea (CDAD) has been reported for tedizolid phosphate (see section 4.8). 
Pri uporabi tedizolid fosfata so poročali o pojavu diareje, povezane z bakterijo Clostridioides difficile (CDAD - Clostridioides difficile associated diarrhoea) (glejte poglavje 4.8).
Sivextro 200 mg powder for concentrate for solution for infusion 
Sivextro 200 mg prašek za koncentrat za raztopino za infundiranje
If less than 8 hours remains before the next dose, then wait until the next scheduled dose. 
Če je do naslednjega odmerka manj kot 8 ur, počakajte do naslednjega načrtovanega odmerka.
Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) 
6.1 Seznam pomožnih snovi manitol natrijev hidroksid (za uravnavanje pH) klorovodikova kislina (za uravnavanje pH)
No evidence of neurotoxicity, including neurobehavioral changes or optic or peripheral neuropathy, was associated with tedizolid after 1, 3, 6 or 9 months of oral administration up to doses with plasma exposure levels (AUC) up to 8-fold greater than the expected human plasma exposure at the oral therapeutic dose. 
Po 1, 3, 6 ali 9 mesecih peroralnega odmerjanja, tudi s tako velikimi odmerki, da je bila plazemska izpostavljenost (AUC) do 8-krat večja od pričakovane plazemske izpostavljenosti pri človeku po peroralnem terapevtskem odmerku, niso s tedizolidom povezali nobenih znakov nevrotoksičnosti, vključno z nevrovedenjskimi spremembami in optično ali periferno nevropatijo.
Tedizolid is a reversible inhibitor of MAO in vitro; however, no interaction is anticipated when comparing the IC50 and the anticipated plasma exposures in man. No evidence of MAO-A inhibition was observed in Phase 1 studies specifically designed to investigate the potential for this interaction. 
Tedizolid je reverzibilen zaviralec monoaminooksidaze (MAO) in vitro, vendar ni pričakovati medsebojnega delovanja, če primerjamo vrednost IC50 za zaviranje MAO-A in pričakovano plazemsko izpostavljenost pri ljudeh.
For administration, the reconstituted solution must be further diluted in 250 mL 0.9% sodium chloride. 
Za uporabo pri bolniku je treba rekonstituirano raztopino dodatno razredčiti v 250 ml 0,9-odstotne raztopine natrijevega klorida.
• Dryness in the nose, congestion in the chest, cough 
• suhost nosne sluznice, nabiranje sluzi v pljučih, kašelj
If a dose is missed it should be given to the patient as soon as possible anytime up to 8 hours prior to the next scheduled dose. 
Če bolnik izpusti odmerek, ga mora prejeti čim prej, in sicer kadar koli do 8 ur pred naslednjim načrtovanim odmerkom.
Renal impairment No dosage adjustment is required (see section 5.2). 
Okvara ledvic Prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
If you miss a dose of Sivextro Tell your doctor or nurse immediately if you are concerned that you may have missed a dose. 
Če niste prejeli odmerka zdravila Sivextro Če vas skrbi, da niste prejeli odmerka zdravila, se takoj posvetujte z zdravnikom ali medicinsko sestro.
If possible, an interruption of the co-administered BCRP substrate medicinal product (such as imatinib, lapatinib, methotrexate, pitavastatin, rosuvastatin, sulfasalazine, and topotecan) should be considered during the 6 days of treatment with oral tedizolid phosphate. 
Če je mogoče, je treba tekom šest-dnevnega zdravljenja s peroralno obliko tedizolid fosfata razmisliti o prekinitvi sočasne uporabe zdravila, ki je substrat BCRP (kot so imatinib, lapatinib, metotreksat, pitavastatin, rosuvastatin, sulfasalazin in topotekan).
Sivextro 200 mg tablets tedizolid phosphate 
Sivextro 200 mg tablete tedizolid fosfat
A second resistance mechanism is encoded by a plasmid-borne and transposon associated chloramphenicol-florfenicol resistance (cfr) gene, conferring resistance in staphylococci and enterococci to oxazolidinones, phenicols, lincosamides, pleuromutilins, streptogramin A and 16membered macrolides. 
Ta gen omogoča stafilokokom in enterokokom odpornost na oksazolidinone, fenikole, linkozamide, plevromutiline, streptogramine A in 16-členske makrolide.
How you will be given Sivextro 
Kako boste prejeli zdravilo Sivextro
Multiple sulfotransferase (SULT) enzymes (SULT1A1, SULT1A2, and SULT2A1) are involved in the biotransformation of tedizolid, to form an inactive and non-circulating sulphate conjugate found in the excreta. 
V biotransformacijo tedizolida je vključenih več encimov sulfotransferaz (SULT1A1, SULT1A2 in SULT2A1).
The highest single dose administered in clinical studies was 1,200 mg. All adverse reactions at this dose level were mild or moderate in severity. 
Največji enkratni odmerek v kliničnih študijah je bil 1.200 mg.
Urticaria 
Driska
Alternative therapies should be considered when treating patients with neutropenia and ABSSSI (see section 5.1). 
Pri bolnikih z nevtropenijo ter akutnimi bakterijskimi okužbami kože in mehkih tkiv je treba razmisliti o drugih možnostih zdravljenja (glejte poglavje 5.1).
For administration, the reconstituted solution must be further diluted in 250 mL of sodium chloride 0.9% solution for injection. 
Za uporabo pri bolniku je treba rekonstituirano raztopino dodatno razredčiti v 250 ml 0,9-odstotne raztopine natrijevega klorida za injiciranje.
White to off-white powder. 
bel do skoraj bel prašek
The safety profile was similar when comparing patients receiving intravenous tedizolid phosphate alone to patients who received oral administration alone, except for a higher reported rate of gastrointestinal disorders associated with oral administration. 
Varnostni profil je bil podoben pri bolnikih, ki so tedizolid fosfat prejemali kot samostojno zdravljenje intravensko, in tistih, ki so zdravilo prejemali kot samostojno zdravljenje peroralno.
Hepatic impairment No dosage adjustment is required (see section 5.2). 
Okvara jeter Prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
Crospovidone Magnesium stearate 
Jedro tablete mikrokristalna celuloza manitol povidon krospovidon magnezijev stearat
Each vial of powder contains disodium tedizolid phosphate which is equal to 200 mg of tedizolid phosphate. 
Ena viala vsebuje dinatrijev tedizolid fosfat, kolikor ga ustreza 200 mg tedizolid fosfata.
In a clinical study comparing the single dose (2 mg) pharmacokinetics of midazolam (CYP3A4 substrate) alone or in combination with tedizolid phosphate (once-daily 200 mg oral dose for 10 days), midazolam AUC and Cmax when co-administered with tedizolid phosphate were 81% and 83% of midazolam AUC and Cmax when administered alone, respectively. 
V klinični študiji, v kateri so primerjali farmakokinetiko enkratnih odmerkov (2 mg) midazolama (substrat CYP3A4) samega ali v kombinaciji s tedizolid fosfatom (200-mg peroralni odmerek enkrat dnevno 10 dni), sta, v primeru sočasne uporabe s tedizolid fosfatom, AUC in Cmax midazolama znašala 81 % oziroma 83 % vrednosti AUC in Cmax v primeru uporabe samega midazolama.
If a dose is missed, it should be taken as soon as possible anytime up to 8 hours prior to the next scheduled dose. 
Če bolnik izpusti odmerek, ga mora vzeti čim prej, in sicer kadar koli do 8 ur pred naslednjim načrtovanim odmerkom.
Sivextro 200 mg film-coated tablets tedizolid phosphate 
Sivextro 200 mg filmsko obložene tablete tedizolid fosfat
If in any doubt, contact your pharmacist for advice. 
Če ste v dvomih, se posvetujte s farmacevtom.
The mechanism of action is different from that of non-oxazolidinone class antibacterial medicinal products; therefore, cross-resistance between tedizolid and other classes of antibacterial medicinal products is unlikely. 
Verjetnost navzkrižne odpornosti med tedizolidom in drugimi skupinami protibakterijskih zdravil je zato majhna.
• Abnormal sense of taste 
• nenormalno okušanje
Sivextro 200 mg powder for concentrate for solution for infusion tedizolid phosphate 
Sivextro 200 mg prašek za koncentrat za raztopino za infundiranje tedizolid fosfat
• Vaginal infection, inflammation or itching 
• okužba, vnetje ali srbenje nožnice
Vulvovaginal mycotic infection Fungal infection Vulvovaginal candidiasis Abscess 
Infekcijske in parazitske bolezni vulvovaginalna glivična okužba glivična okužba vulvovaginalna kandidiaza absces kolitis zaradi okužbe s Clostridioides difficile dermatofitija oralna kandidiaza okužba dihal
In a clinical study comparing the single dose (10 mg) pharmacokinetics of rosuvastatin (Breast Cancer Resistant Protein [BCRP] substrate) alone or in combination with tedizolid phosphate (once-daily 200 mg oral dose), rosuvastatin AUC and Cmax increased by approximately 70% and 55%, respectively, when coadministered with tedizolid phosphate. 
V klinični študiji, v kateri so primerjali farmakokinetiko enkratnih odmerkov (10 mg) rosuvastatina (substrat proteina odpornosti pri raku dojke [BCRP - Breast Cancer Resistance Protein]) samega ali v kombinaciji s tedizolid fosfatom (200-mg peroralni odmerek enkrat dnevno), sta se, v primeru sočasne uporabe s tedizolid fosfatom, AUC in Cmax rosuvastatina zvišala; AUC za približno 70 % in Cmax za približno 55 %.
Talk to a doctor if you do not feel better, or if you feel worse after 6 days. 
Če se v 6 dneh znaki vaše bolezni ne izboljšajo ali se še poslabšajo, se posvetujte z zdravnikom.
In a clinical study comparing the single dose (10 mg) pharmacokinetics of rosuvastatin (BCRP substrate) alone or in combination with the oral administration of tedizolid phosphate 200 mg, rosuvastatin AUC and Cmax increased by approximately 70% and 55%, respectively, when coadministered with Sivextro. 
V klinični študiji, v kateri so primerjali farmakokinetiko enkratnih odmerkov (10 mg) rosuvastatina (substrat BCRP) samega ali v kombinaciji s peroralno obliko tedizolid fosfata v odmerku 200 mg, sta se, v primeru sočasne uporabe z zdravilom Sivextro, AUC in Cmax rosuvastatina zvišala; AUC za približno 70 % in Cmax za približno 55 %.
Infusion related reaction Peripheral oedema 
bolečina na mestu infundiranja razdražljivost pireksija z infuzijo povezana reakcija periferni edem
• Swollen or enlarged lymph nodes 
• zatečene ali povečane bezgavke
The reconstituted solution should be inspected visually for particulate matter prior to administration. 
Rekonstituirano raztopino je treba pred uporabo pregledati in se prepričati, da ne vsebuje nobenih delcev.
Peripheral neuropathy, as well as optic neuropathy sometimes progressing to loss of vision, have been reported in patients treated with another member of the oxazolidinone class with treatment durations exceeding that recommended for tedizolid phosphate. 
Med zdravljenjem z drugim zdravilom iz skupine oksazolidinonov v daljšem obdobju od priporočenega za tedizolid fosfat so poročali o periferni nevropatiji kot tudi o nevropatiji očesnega živca, ki je nekajkrat napredovala v izgubo vida.
Diabetes mellitus inadequate control 
Bolezni imunskega sistema preobčutljivost za zdravilo
Talk to your doctor or nurse before being given Sivextro if any of the following apply to you: - are suffering from diarrhoea, or have suffered from diarrhoea whilst (or up to 2 months after) being treated with antibiotics in the past. 
Preden prejmete zdravilo Sivextro se posvetujte z zdravnikom ali medicinsko sestro, če kar koli od naštetega velja za vas: - če imate drisko ali ste v preteklosti imeli drisko med uporabo antibiotikov (ali do 2 meseca po uporabi); - če ste alergični na druga zdravila, ki spadajo v skupino "oksazolidinonov" (npr. linezolid, cikloserin); - če jemljete zdravila za zdravljenje depresije, ki se imenujejo triciklični antidepresivi, antidepresivi vrste SSRI (selektivni zaviralci ponovnega privzema serotonina) ali zaviralci MAO (zaviralci monoaminooksidaze), za primere glejte Druga zdravila in zdravilo Sivextro; - če jemljete zdravila proti migreni, ki se imenujejo "triptani," za primere glejte Druga zdravila in zdravilo Sivextro.
Sivextro 200 mg powder for concentrate tedizolid phosphate 
Sivextro 200 mg prašek za koncentrat tedizolid fosfat i.v.
Reproductive system and breast disorders 
Motnje reprodukcije in dojk vulvovaginalni pruritus
Decreased platelets, decreased haemoglobin and decreased neutrophils have been observed in a few subjects during treatment with tedizolid phosphate. 
Med zdravljenjem s tedizolid fosfatom so pri nekaj preiskovancih opazili zmanjšano število trombocitov, znižano raven hemoglobina in zmanjšano število nevtrofilcev.
Certain side effects have been observed with another member of the oxazolidinone class when administered over a duration exceeding that recommended for Sivextro. 
Pri drugem zdravilu iz skupine oksazolidinonov, ko so ga uporabljali v daljšem časovnem obdobju od priporočenega za zdravilo Sivextro, so opazili nekatere neželene učinke.
In rats, decreased foetal weights and increased skeletal variations including reduced ossification of the sternabrae, vertebrae, and skull were observed at the high dose of 15 mg/kg/day (6-fold the estimated human exposure based on AUCs) and were associated with maternal toxicity (reduced maternal body weights). 
Pri podganah so pri velikem odmerku 15 mg/kg/dan (6-kratnik ocenjene ravni izpostavljenosti pri človeku, ki temelji na vrednostih AUC) opazili zmanjšano maso plodu in povečane variacije skeleta, vključno z zmanjšano okostenelostjo prsnice, vretenc in lobanje.
A second resistance mechanism is encoded by a plasmid-borne and transposon associated chloramphenicol-florfenicol resistance (cfr) gene, conferring resistance in staphylococci and enterococci to oxazolidinones, phenicols, lincosamides, pleuromutilins, streptogramin A and 16-membered macrolides. 
Drugi mehanizem odpornosti temelji na genu za odpornost na kloramfenikol/florfenikol (cfr), ki ga prenašajo plazmidi in je povezan s transpozoni.
• bleeding or bruising easily 
• nagnjenost h krvavitvam ali podplutbam,
Infusion 
Infundiranje
Nasal dryness Pulmonary congestion 
Žilne bolezni zardevanje vročinski oblivi
Serotonergic agents 
Serotoninergične učinkovine
Povidone 
Redčenje